Introduction {#sec1}
============

Recently, advances in medical technology have led to active and aggressive major hepatectomies. However, hepatic failure is still a fatal complication and is seen in 2.5% to 12.9% of patients \[[@cit0001]-[@cit0003]\]. Preoperative percutaneous transhepatic portal vein embolisation (PTPE) is known as an effective means of preventing hepatic failure by functional residual liver hypertrophy and is often performed. However, a variety of hepatic injuries, such as liver cirrhosis, as well as post-systemic chemotherapy, greatly affect the outcomes of PTPE. Although morphological computed tomography (CT) volumetry has been widely used as an easy method of evaluation before and after PTPE, it is not suitable for accurately measuring functional residual liver volume.

To date, the usefulness of Tc-99m galactosyl human serum albumin (GSA) scintigraphy for more accurate evaluation of underlying liver diseases, such as cirrhosis \[[@cit0004],[@cit0005]\], during both the preoperative \[[@cit0002],[@cit0003],[@cit0006]\] and peri-PTPE period \[[@cit0007],[@cit0008]\], have been reported. A variety of radionuclide parameters can be used for Tc-99m GSA scintigraphy, depending on the institute. Residual liver uptake at 15 minutes (RLU15), which was reported by Koizumi *et al*., is the cumulative residual liver accumulation rate of a GSA tracer 15 minutes after its injection, and it indicates residual liver function \[[@cit0009]\]. To safely perform hepatectomies, it has been reported that the RLU15 should theoretically \[[@cit0010]\] and clinically \[[@cit0002]\] be 13 or more. A co-author of the present manuscript has already reported the usefulness of using RLU15 to predict liver failure \[[@cit0002]\]; however, to date, there has been no evaluation of the effectiveness of PTPE using RLU15. We report herein a correlation between morphological residual liver volume (RLV) and RLU15 before and after PTPE in 20 patients, and also compare the rate of increase in RLV and RLU15 between two groups, diagnosed and evaluated as having pathological cirrhosis vs. non-cirrhosis, and post-chemotherapy vs. non-chemotherapy.

Material and methods {#sec2}
====================

Patient characteristics and underlying liver disease {#sec2.1}
----------------------------------------------------

Patient characteristics are listed in [Table 1](#t0001){ref-type="table"}. Between August 2010 and December 2016, 30 patients underwent preoperative PTPE. Ten of them were excluded because data on either contrast-enhanced computed tomography (CECT) or Tc-99m GSA scintigraphy were missing, and therefore 20 patients (14 men and six women, median age: 72 years, range 42-78 years) were selected as subjects for the present study. Six patients were diagnosed as having hepatocellular carcinoma (HCC), six were diagnosed as having cholangiocarcinoma, and eight were diagnosed as having metastases from colorectal cancer (MT). Five out of six MT patients underwent systemic chemotherapy before PTPE.

###### 

Patient characteristics

  Patient no.   Age (years)/Sex   Diagnosis   Embolised portal vein branch   Underlying liver disease   Interval to follow-up imaging from PTPE procedure (days)          
  ------------- ----------------- ----------- ------------------------------ -------------------------- ---------------------------------------------------------- ------ ------
  1             71/M              HCC         Right                          No                         No                                                         22     22
  2             77/M              MT          Right                          No                         No[\*](#tf1-1){ref-type="table-fn"}                        27     48
  3             73/M              CC          Right                          No                         No                                                         13     14
  4             61/M              HCC         Right                          Yes, 3                     No                                                         21     21
  5             74/M              CC          Right                          No                         No                                                         21     20
  6             64/M              HCC         Right                          Yes, 4                     No                                                         24     25
  7             42/F              MT          Right                          No                         Yes, O (6), mild CASH                                      17     17
  8             70/F              MT          Right                          No                         Yes, O+I (2), mild SOS                                     21     18
  9             76/M              HCC         Right                          No                         No                                                         25     29
  10            49/M              MT          Right                          No                         Yes, O (6), moderate CASH                                  27     27
  11            68/M              MT          Right                          No                         Yes, O (6), moderate SOS                                   18     17
  12            72/M              CC          Right                          No                         No                                                         18     20
  13            72/F              CC          Right                          Yes, 3                     No                                                         7      17
  14            72/M              CC          Right                          No                         No                                                         21     15
  15            72/F              CC          Left + Ante                    −                          No                                                         17     17
  16            78/M              CC          Left + Ante                    No                         No                                                         52     25
  17            79/M              HCC         Left + Ante                    −                          No                                                         23     23
  18            75/F              CC          Right                          −                          No                                                         25     25
  19            73/M              HCC         Post + P4                      No                         No                                                         28     28
  20            77/F              MT          Right                          No                         Yes, O (4), moderate SOS                                   13     13
  Median        72                                                                                                                                                 21.0   20.5

HCC -- hepatocellular carcinoma; CC -- cholangiocarcinoma; MT -- metastasis from colorectal cancer; Ante -- Anterior; Post -- Posterior; P4 -- portal vein into segment 4; CECT -- contrast-enhanced computed tomography; PTPE -- percutaneous transhepatic portal vein embolization; O -- oxaliplatin-based chemotherapy; O+I -- irinotecan-based chemotherapy followed by oxaliplatin-based chemotherapy; CASH -- chemotherapy-associated steatohepatitis; SOS -- sinusoidal obstructive syndrome

Heterochronous metastasis was detected and the patient did not receive systemic chemotherapy before PTPE. The other patients with MT all had homochronous metastasis and received systemic chemotherapy before PTPE.

Interventional radiology devices and embolic agents {#sec2.2}
---------------------------------------------------

A 6-Fr long sheath and a J-curved and loop-shaped 5.5-Fr balloon catheter (Selecon MP catheter II, Terumo, Tokyo, Japan) were used in every procedure ([Figure 1](#f0001){ref-type="fig"}). Absolute ethanol (Absolute Ethanol^TM^, FUSO Pharmaceutical Industries, Ltd., Osaka, Japan) was used as an embolic material in all cases and was also used for the ethanol-lipiodol mixture, which contained 2 ml of ethiodised oil (Lipiodol^TM^, Guerbet Japan, Tokyo, Japan) and 8 ml of ethanol. The maximum dose of ethanol was decided to be less than 0.2 ml/kg of body weight, which was considered a safe dose. Gelatine sponges (GS, Serescue^TM^ Nippon Kayaku Co., Ltd., Tokyo, Japan) were used for approach tract embolisation.

![Photographs of the balloon catheters that were used. The size of the catheters was 5.5 Fr, and 2 types of tips, namely J-shaped and loopshaped, were used](PJR-83-81155-g001){#f0001}

PTPE procedure {#sec2.3}
--------------

A routine method by which we perform embolisation of the portal vein branch of the right hepatic lobe is described below, which is similar to the PTPE outline using absolute ethanol reported by Satake *et al*. \[[@cit0011]\]. In all cases, the percutaneous transhepatic and ipsilateral approach was used. The portal vein of segment no. 5 (P5) or P6 was usually punctured with a 21-G needle under ultrasound guidance. A 6-Fr long sheath and a 5.5-Fr loop-shaped balloon catheter was coaxially inserted and advanced to the main trunk of the portal vein. Digital subtraction angiography (DSA) was performed, and whole portal vein images were confirmed ([Figure 2A](#f0002){ref-type="fig"}). A loop was made at the tip of the balloon catheter within the splenic vein. The tip of the catheter was inserted into the anterior branch of the portal vein and the balloon was inflated at the beginning of the anterior branch. Selective DSA was performed from this point ([Figure 2B](#f0002){ref-type="fig"}), which was also a test injection. The ethanol and lipiodol mixture was carefully and slowly injected to avoid backflow, particularly back into the left portal branch ([Figure 2C](#f0002){ref-type="fig"}). The dose of the embolic material was set at approximately the same as that of the test injection. Next, a 10-minute wait was necessary, until the endothelium of the portal vein became damaged and an embolic effect appeared. The balloon catheter was removed, DSA was performed from the sheath, and we confirmed that the embolised anterior branch of the portal vein was not displayed on the image. Next, the other J-curved balloon catheter was inserted into the portal vein trunk, and the tip of the balloon was placed on the beginning of the posterior branch as distally as possible because this makes portal vein reconstruction easier for the surgeon during hepatectomy. Selective DSA (test injection) was performed during balloon occlusion ([Figure 2D](#f0002){ref-type="fig"}). The ethanol-lipiodol mixture was injected from the sheath at the same dose as the test injection ([Figure 2E](#f0002){ref-type="fig"}). Finally, access tract embolisation was necessary to prevent bleeding from the puncture site ([Figure 3](#f0003){ref-type="fig"}). A GS was cut into equal-sized thin strips, which were rounded into a cylindrical shape ([Figure 3C](#f0003){ref-type="fig"}). A second sheath was prepared and cut at approximately 5 cm intervals ([Figure 3D](#f0003){ref-type="fig"}), and the cylindrical shaped GS was put into the cylindrical cut sheath. The cut sheath within the GS was inserted from behind of the first sheath, and the GS was pushed into the tract by the inner cylinder with a guidewire from behind the first sheath, and the tract was packed with GS in the form of a mould ([Figure 3E](#f0003){ref-type="fig"}).

![Digital subtraction angiography (DSA) during the percutaneous transhepatic portal vein embolisation (PTPE) procedure. **A**) The tip of the sheath was placed on the trunk of the portal vein, and contrast material was injected into the liver. The entire portal vein trunk and branches were displayed. **B**) A loop-shaped balloon catheter was turned back at the splenic vein and then its tip was inserted into the anterior segment branch, and after balloon occlusion, DSA of the anterior segment branch was performed. **C**) The ethanol-lipiodol mixture was carefully injected into the anterior segment branch while confirming the absence of reflux. **D**) A J-shaped balloon catheter was inserted into the beginning of the posterior branch, the balloon was occluded, and the contrast material was injected from the sheath. **E**) The ethanol-lipiodol mixture was carefully injected into the posterior segment branch while confirming the absence of reflux. **F**) In the final image, the portal vein of the right lobe was completely embolised, and only the portal vein of the left lobe was visualised](PJR-83-81155-g002){#f0002}

![Photographs demonstrating tract embolisation. **A**) The percutaneous transhepatic tract (arrows) is embolised to prevent bleeding from the puncture site. **B**) A gelatine sponge (GS) and a sharp disposable pointed scalpel. **C**) The GS was cut into 2-mm rectangular strips and manually rounded into a cylindrical shape. **D**) A new sheath was divided into three equal parts of about 5 cm (arrows), and the cut GS was put into the cut sheath. The GS was soaked with a small amount of contrast agent. **E**) This cut sheath (black arrow) was inserted into the first sheath (white arrow) and pushed with the inner tube (white arrowhead) under fluoroscopy. **F**) The tract was embolised completely in the shape of the mould (arrows)](PJR-83-81155-g003){#f0003}

Parameters and evaluation items {#sec2.4}
-------------------------------

Before and approximately three weeks after PTPE, CECT and Tc-99m GSA scintigraphy were performed. The RLV and the RLU15 were used as the main parameter. CT volumetry, including RLV, was calculated by Synapse Vincent (Fujifilm Holdings Corporation, Tokyo, Japan). Liver uptake at 15 minutes (LU15) is the ratio of cumulative liver uptake from 15 to 16 minutes after GSA administration divided by the total GSA dose, and its formula is as below \[[@cit0009]\].
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C (t) is the time-activity curves in which the region of interest is set in the liver in a continuous image taken from the anterior surface. RLU15 is the value obtained by multiplying LU15 by the residual count ratio calculated from single-photon emission computed tomography. When evaluating residual liver function before hepatectomy, the desirable RLU15 value is reported to be more than 13 \[[@cit0010]\].

As the primary endpoint, RLV, RLU15, the fold change in RLV (DRLV), the fold change in RLU15 (DRLU15), and correlation between DRLV and DRLU15 were obtained. DRLV and DRLU 15 were calculated as follows:

Δ

RLV

=

after

RLV

before

RLV

,

Δ

RLV

15

=

after

RLT15

before

RLU15

The samples of 16 patients who underwent radical hepatectomy were histopathologically evaluated. The liver cirrhosis group was defined as cases of fibrosis grade (F) 3 or F4 pathologically diagnosed according to the classification reported by Desmet *et al*. \[[@cit0012]\].

Sinusoidal obstructive syndrome (SOS) and chemotherapy-associated steatohepatitis (CASH) are well-known hepatic impairments caused by systemic chemotherapy for colorectal cancer, and they were evaluated based on the scores reported by Rubbia-Brandt *et al*. \[[@cit0013]\]. DRLV and DRLU15 were compared between the two groups, i.e. the cirrhosis group (*n* = 3) vs. the non-cirrhosis group (*n* = 13), and the chemotherapy group (*n* = 5) vs. the non-chemotherapy group (*n* = 15).

As a secondary endpoint, % future remnant liver (FRL) change rates (increase %FRL) were calculated using the following formulas:
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(FRLV -- future remnant liver volume; TLV -- total liver volume; TV -- tumour volume)

Adverse events were evaluated using CTCAE v4.0 software.

Statistical analysis {#sec2.5}
--------------------

Ratios were expressed as means and standard deviations. For the differences in increases in RLV and RLU15 before and after PTPE, Student's *t*-test was used. For two-group comparisons, Wilcoxon's rank sum test was used. A *p*-value less than 0.05 was considered to indicate a significant difference between two groups.

Results {#sec3}
=======

The median amount of ethanol used was 7.5 (3.67-10.0) ml. The embolic areas were the right lobe in 16 patients and the three segments in four patients. Of these four patients three were embolised in the left lobe and anterior segment, and one was embolised in the right lobe and segment 4. The median intervals from PTPE to CECT, to Tc-99m GSA scintigraphy, and to surgery were 21 (7-52) days, 21 (13-48) days, and 31 (20-56) days, respectively. Radical resection was performed in 16 patients (curative hepatectomy rate: 80%), and these patients were pathologically evaluated. In the other four patients (nos. 15, 17, 18, and 19), hepatectomy was not performed because the progression of the original disease was seen ([Table 2](#t0002){ref-type="table"}).

###### 

Morphological and functional parameters obtained from PTPE, PTPE complications, and follow-up

  Patient no.   RLV (ml)   RLU15 (%)            Complications   Radical resection\*   Reason that radical resection could not be performed                                                         
  ------------- ---------- -------------------- --------------- --------------------- ------------------------------------------------------ ------------- --------------------------------- ----- ------------------------
  1             418        516                  1.23            8.5                   14.2                                                   1.67          −                                 Yes   −
  2             501        598                  1.19            9.8                   17.6                                                   1.80          −                                 Yes   −
  3             378        360                  0.95            5.9                   11.4                                                   1.93          −                                 Yes   −
  4             541        693                  1.28            11.0                  19.4                                                   1.76          −                                 Yes   −
  5             459        562                  1.22            4.3                   7.6                                                    1.77          −                                 Yes   −
  6             481        675                  1.40            10.6                  16.8                                                   1.58          −                                 Yes   −
  7             519        625                  1.20            16.5                  22.9                                                   1.39          −                                 Yes   −
  8             313        470                  1.50            7.5                   18.0                                                   2.40          −                                 Yes   −
  9             553        633                  1.14            10.3                  22.9                                                   2.22          −                                 Yes   −
  10            558        748                  1.36            10.9                  17.2                                                   1.58          ALT and AST elevation (grade 4)   Yes   −
  11            612        637                  1.04            13.6                  17.3                                                   1.27          −                                 Yes   −
  12            687        845                  1.23            10.3                  18.6                                                   1.61          −                                 Yes   −
  13            495        616                  1.24            11.0                  22.0                                                   1.69          −                                 Yes   −
  14            445        609                  1.37            12.2                  22.0                                                   1.80          −                                 No    Multiple dissemination
  15            406        484                  1.19            13.0                  16.7                                                   1.28          −                                 Yes   −
  16            391        592                  1.51            14.7                  15.0                                                   1.02          Cholangitis                             
  (grade 3)     No         Tumour progression                                                                                                                                                      
  17            509        492                  0.97            12.7                  15.2                                                   1.20          −                                 No    Tumour progression
  18            358        456                  1.27            14.8                  21.9                                                   1.48          −                                 No    Tumour progression
  19            297        411                  1.38            10.1                  18.8                                                   1.86          −                                 Yes   −
  20            348        437                  1.26            11.9                  23.9                                                   1.93          −                                 Yes   −
  Mean          464 ± 99   573 ± 118            1.25 ± 0.15     11.0 ± 2.9            17.7 ± 3.8                                             1.66 ± 0.33                                           

PTPE -- percutaneous transhepatic portal vein embolisation; RLV -- residual liver volume; RLU15 -- residual liver uptake at 15 minutes

Primary endpoint {#sec3.1}
----------------

Total liver volume before and after PTPE were 1304 ± 278 ml and 1249 ± 254 ml, respectively, and no significant difference was seen (*p* = 0.53). A significant increase was observed in the RLV (464 ± 99 ml and 573 ± 118 ml, *p* = 0.004, [Figure 4](#f0004){ref-type="fig"}) before and after PTPE. DRLV in all cases was 1.25 ± 0.15. Total liver LU15 before and after PTPE were 28.8 ± 4.9% and 27.3 ± 4.9%, respectively, which indicated no significant difference (*p* = 0.35). The RLU 15 before and after PTPE were 11.0 ± 2.9% and 17.7 ± 3.8%, respectively, with a significant increase (*p* = 5 × 10^-7^, [Figure 4](#f0004){ref-type="fig"}). DRLU15 in all cases was 1.66 ± 0.33. No significant correlation was observed in either RLV or RLU15 before and after PTPE (*r* = 0.14, *p* = 0.66, [Figure 5A](#f0005){ref-type="fig"}), although both RLV and RLU15 were significantly increased. Outliers were patients nos. 3, 9, and 16, and after these patients were excluded, the correlation coefficient increased to 0.76 (*p* = 0.005, [Figure 5B](#f0005){ref-type="fig"}). The results of these three outliers are shown in [Table 3](#t0003){ref-type="table"}. In patients nos. 3 and 9 there was a minimal increase in RLV and a large increase in RLU15, and these two patients were able to undergo radical hepatectomy after PTPE. Patient no. 16 showed a large increase in RLV and a small increase in RLU15, and radical hepatectomy could not be completed because of tumour progression. The outcomes of the two-group comparisons are listed in [Table 4](#t0004){ref-type="table"}. Pathological cirrhosis was observed in patients nos. 5, 7, and 14 ([Figure 6A](#f0006){ref-type="fig"}), and the other 13 patients, including those with HCC, had no obvious fibrosis. There were no significant differences between cirrhotic and non-cirrhotic groups regarding both DRLV (1.28 vs. 1.22, *p* = 0.12) and DRLU15 (1.69 vs. 1.77, *p* = 0.59). Five patients (nos. 7, 8, 10, 11, and 20) underwent two to six courses of systemic chemotherapy before PTPE. Oxaliplatin-based chemotherapy was performed in these five patients. Only one patient (no. 8) switched to irinotecan-based chemotherapy because of an allergy to oxaliplatin ([Table 1](#t0001){ref-type="table"}). No significant differences were observed between chemotherapy and non-chemotherapy groups in both DRLV (1.26 vs. 1.23, *p* = 0.76) and DRLU 15 (1.58 vs. 1.69, *p* = 0.97).

###### 

Outliers of the RLV and RLU15 results

                                    Patient no.   ΔRLV   ΔRLU15   Outcomes
  --------------------------------- ------------- ------ -------- --------------------------------------------------------------------------------------------------------
  Outliers of the RLV results       3             0.95   1.93     Radical hepatectomy was performed
  9                                 1.14          2.22            
  An outlier of the RLU15 results   16            1.51   1.02     Progression of the present disease was confirmed during surgery and hepatectomy could not be performed

###### 

Outcomes of patients with cirrhotic liver vs. non-cirrhotic liver and patients undergoing systemic chemotherapy vs. no systemic chemotherapy before PTPE

           Cirrhotic (3) vs. non-cirrhotic (13)   *p*-value   Chemo (5) vs. no chemo (15)   *p*-value
  -------- -------------------------------------- ----------- ----------------------------- -----------
  ΔRLV     1.28 vs. 1.22                          0.12        1.26 vs. 1.23                 0.76
  ΔRLU15   1.69 vs. 1.77                          0.59        1.58 vs. 1.69                 0.97

![Changes in residual liver volume (RLV) and residual liver uptake at 15 minutes (RLU15) before and after PTPE. The RLV (before: 464 ± 99 ml; after: 573 ± 118 ml, *p* = 0.004) and RLU 15 (before: 11.0 ± 2.9%; after: 17.7 ± 3.8%, *p* = 5 × 10-7) were significantly increased after PTPE](PJR-83-81155-g004){#f0004}

![Correlation between rates of changes in RLV and RLU15. **A**) When all patients were analysed, no correlation was observed (*r* = 0.14, *p* = 0.66). The three outliers were patients nos. 3, 9, and 16 (arrows). **B**) When the three outliers were excluded, a positive correlation was obtained (*r* = 0.76, *p* \< 0.005)](PJR-83-81155-g005){#f0005}

![Photographs of liver pathology of three representative patients. All samples were stained with haematoxylin and eosin; original magnification: ×40. The sample in (A) was prepared for the evaluation of fibrotic grade, and (B) and (C) were prepared to evaluate post-chemotherapeutic effects. **A**) Patient no. 6 was evaluated as fibrosis grade 4. **B**) Patient no. 10 underwent six courses of FOLFOX with Bevacizumab and was concluded to have moderate CASH (stenosis in 30% of hepatocytes). **C**) Patient no. 20 received four courses of FOLFOX with Bevacizumab and was concluded to have moderate SOS (centrilobular involvement of two-thirds of the lobular surface)](PJR-83-81155-g006){#f0006}

Secondary endpoint {#sec3.2}
------------------

The % FRL increase was 34.4 ± 25.2%. At the time of injection of ethanol, local abdominal pain was recognised in all patients; however, it was under self-control by the administration of analgesics. Major adverse events are listed in [Table 2](#t0002){ref-type="table"}. Grade 3 cholangitis, which requires endoscopic retrograde biliary drainage (ERBD), was found in one patient. Grade 4 alanine aminotransferase (ALT) and aspartate transaminase (AST) elevation were observed in one patient, grade 3 ALT elevation in 10 patients, grade 3 AST elevation in seven patients, grade 3 bilirubin elevation in one patient, and grade 3 thrombocytopenia in one patient; however, these symptoms were adequately treated by conservative treatments. Regarding postembolic syndromes, grade 1 fever was observed in five patients, grade 2 nausea in five patients, and grade 1 vomiting in one patient.

Discussion {#sec4}
==========

Some studies have compared morphological RLV with residual liver function (RLF), which is another radionuclide parameter that is different from RLU15 obtained from Tc-99m GSA scintigraphy, before and after PTPE \[[@cit0007],[@cit0008],[@cit0014]\]. The fold change in RLV and RLF were 1.28 to 1.32 and 1.63 to 1.7, respectively, and generally, the increase in the rate of change in RLF is known to be much greater than that of RLV \[[@cit0003],[@cit0006],[@cit0008],[@cit0015]\]. In the present study, the fold changes in RLV and RLU15 were 1.25 ± 0.15 and 1.66 ± 0.33, respectively, which is equivalent to those of previous reports. No correlation was seen between the fold change in RLV and RLU15 in all patients. Kono *et al*. reported that no correlation was observed between morphological RLV and residual liver R max (a radionuclide parameter) before and after PTPE in all patients (*r* = 0.105, *p* = 0.803) \[[@cit0008]\]. A good correlation between these parameters was observed when the patients were narrowed down to the good response group that showed a large increase in R max (*r* = 0.826, *p* = 0.037). Nanashima *et al*. found a good correlation between CT volumetry before PTPE and RI volumetry (*r* = 0.69); however, a very weak correlation was found between CT volumetry and RI volumetry after PTPE (*r* = 0.03) \[[@cit0015]\]. From these previous reports, it is suggested that although PTPE increases both RLV and RLF, these parameters may not be simply well correlated. Therefore, it is clinically important and desirable to analyse both parameters for more accurate evaluation of liver function. We divided the outliers into two types. Type A, comprising two of the three outliers, showed a small increase in RLV but a large increase in RLU15 ([Table 3A](#t0003){ref-type="table"}). Type B, comprising one of the three outliers, showed a large increase in RLV but a small increase in RLU15 ([Table 3B](#t0003){ref-type="table"}). Compared with morphological RLV, RLF values obtained from GSA scintigraphy are known to be better correlated with postoperative albumin level \[[@cit0015]\], prothrombin time \[[@cit0010]\], total bilirubin \[[@cit0010],[@cit0015]\], preoperative indocyanine green retention rate at 15 min (ICGR 15) \[[@cit0009],[@cit0010]\], and postoperative indocyanine green \[[@cit0006],[@cit0015]\]. Therefore, in patients of type A, even if only a small increase in RLV is observed, a large increase in RLU15 is likely to indicate sufficient regeneration of the residual liver. As a result, we were able to perform surgery on all type A patients. On the other hand, in type B, two hypotheses were clinically inferred. The first hypothesis was that the underlying liver disease was much worse, and liver regeneration might take a comparatively long time. The remnant liver is known to continue to undergo hypertrophy after PTPE and postoperatively \[[@cit0003],[@cit0015]\]. The second hypothesis was that there was rapid progression of the present liver disease and that regeneration itself was poor. In the case of patient no. 16, the latter hypothesis was thought to be true because progression of the present disease was found during surgery and hence curative operation was not performed. Many studies have reported that sufficient RLV and RLF increases in patients with liver cirrhosis may not be observed after PTPE \[[@cit0003],[@cit0016]-[@cit0019]\]. In the present study, the fold change in RLV appeared to be good (1.28), but the RLU15 remained at 1.69. In the case of cirrhotic patients, Kono *et al*. speculated that an increase in RLV reflects not an increase in the number of functional hepatocytes but instead an increase in the interstitial area \[[@cit0008]\]. This hypothesis suggests that in patients with liver cirrhosis, even if a good increase in RLV is observed, careful evaluation is required. To our knowledge, there are few studies comparing RLF in post-chemotherapy and non-chemotherapy groups before and after PTPE. Patients undergoing systemic chemotherapy after PTPE did not show a significant decrease in the rate of increase in RLV compared with the non-chemotherapy group \[[@cit0017],[@cit0020],[@cit0021]\]. On the other hand, de Baere *et al*. found that the rate of increase in RLV significantly decreased in the patient group, using the platinum formulation \[[@cit0022]\]. Narita *et al*. reported that the rate of increase in RLV significantly decreased in the SOS group (16.8 ± 24.0 vs. 55.6 ± 32.5, *p* \< 0.001) \[[@cit0023]\]. The median number of chemotherapy cycles was 10 (range, 2-44), and the grades of SOS were mild in five patients, moderate in four patients, and severe in two patients. Ninety per cent of the patients with SOS received more than six cycles of chemotherapy and/or underwent oxaliplatin-based chemotherapy. In the present study, the chemotherapy group had equivalent outcomes in both RLV and RLU15 compared with the non-chemotherapy group, and consequently, curative hepatectomy was performed. Five cases in the chemotherapy group were pathologically evaluated, as follows: Moderate SOS was found in patients nos. 11 and 20, mild SOS in patient no. 8, moderate CASH was seen in patient no. 10, and mild CASH was seen in patient no. 7. No severe cases of both SOS and CASH were observed. An insufficient increase in RLU15 was observed only in patient no. 11. Thus, for up to six cycles of chemotherapy, it seems that systemic chemotherapy before PTPE might not affect increases in RLV and RLU15.

According to a systematic review of PTPE, % FRL was used for calculating the hypertrophy response of residual liver in 68.2% of reported studies \[[@cit0017]\]. The average and width of % FRL volume increase were used in 37.9 ± 0.1% and 20.5% to 69.4%, respectively. Sakuhara *et al*. reported that, in a study of 143 patients who underwent PTPE using ethanol, the % FRL volume increase and resection rate were 33.6% and 84%, respectively \[[@cit0024]\]. In the present study, the % FRL volume increase and resection rate were 34.4 ± 25.2% and 80%, respectively, which were similar to the previous study. The rate of PTPE complications was reported as 2.2% to 15% \[[@cit0025]-[@cit0027]\]. As a mild complication that is specific to the use of ethanol, pain at the time of injection may be reported. However, in our present study, most cases of pain were relieved within a few minutes with or without analgesics, similarly to a previous publication \[[@cit0024]\]. Pneumothorax, cholangitis, PVT, etc. were reported as major complications \[[@cit0025]-[@cit0027]\]. Rare but fatal cases of pulmonary embolism and cholangitis after PTPE have been reported \[[@cit0028]\]. In the present study, patient no. 16 had cholangitis on day 12 after PTPE, and although ERBD had been performed 14 days before PTPE, it was performed again. Radical hepatectomy was attempted after two months; however, the tumour was unresectable due to tumour progression. A serious complication after PTPE was only observed in this patient.

Limitations {#sec5}
===========

This study has several limitations. Firstly, it is a retrospective study with only a few patients. All pathological specimens were obtained after surgery, and therefore they were affected by both PTPE and surgery. As hypertrophy of the residual liver continues even after hepatectomy, the final postoperative residual liver function was not evaluated. The outcomes after hepatectomy appear to most greatly affect the patients' prognosis; however, the success rate of the operation depends not only on residual liver function but also on operation time, amount of bleeding, and whether or not vascular reconstruction was performed. In the present study, the effect of pure PTPE was evaluated.

Conclusions {#sec6}
===========

No correlation was found between rates of changes in RLV and RLU15 both before and after PTPE. Outliers in which RLU15 increased despite a small increase in RLV suggested that these may be cases in which to consider surgery. Severe liver injury did not occur upon systemic chemotherapy for up to six cycles, and the effects of PTPE were similar to those in patients with liver cancer, who did not receive chemotherapy.
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